Compare ARK Genomic Revolution ETF (ARKG) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Bristol-Myers Squibb Co — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Bristol-Myers Squibb Co trades at $57.55 (market cap $117.58B). The key difference: Bristol-Myers Squibb Co pays a 4.38% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| ARKG | BMY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $62.37 |
52-Week Low | $23.09 | $42.60 |
Market Cap | — | $117.58B |
Enterprise Value | — | $153.52B |
Dividend Yield | — | 4.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Bristol Myers Squibb (BMY) trades at $57.58, down 0.62% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 70.46% gross margin and 15.01% net income margin, though it faces a patent cliff risk. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.58 surpassing the $1.42 estimate. Analyst consensus shows a mixed but leaning positive view with 46% buy ratings and a $60 price target.
BMY offers value with a reasonable P/E of 16.13 and attractive 4.3% dividend yield, supported by 36 years of uninterrupted payments. However, investors must weigh the patent expiration headwinds against the company's growth portfolio, which now represents 54.1% of revenues. The stock presents a balanced opportunity for income-focused investors with moderate growth potential amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
